<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>S3098</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Albertus Extra Bold";
	panose-1:2 14 8 2 4 3 4 2 2 4;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-link:"Document Map Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	background:navy;
	font-size:12.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:9.0pt;
	font-family:"Segoe UI",sans-serif;
	letter-spacing:.2pt;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Calibri",sans-serif;}
span.11ptChar
	{mso-style-name:11ptChar;
	font-family:"Times New Roman",serif;}
span.BillHead
	{mso-style-name:BillHead;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillHeading2
	{mso-style-name:BillHeading2;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillHeadUnBold
	{mso-style-name:BillHeadUnBold;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
span.BillLanguage
	{mso-style-name:BillLanguage;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.bpuBill, li.bpuBill, div.bpuBill
	{mso-style-name:bpuBill;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:26.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuHeadSpon, li.bpuHeadSpon, div.bpuHeadSpon
	{mso-style-name:bpuHeadSpon;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.bpuHeadSponChar
	{mso-style-name:bpuHeadSponChar;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuIntro, li.bpuIntro, div.bpuIntro
	{mso-style-name:bpuIntro;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.bpuLegislature, li.bpuLegislature, div.bpuLegislature
	{mso-style-name:bpuLegislature;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:24.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuNormText, li.bpuNormText, div.bpuNormText
	{mso-style-name:bpuNormText;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuReprint, li.bpuReprint, div.bpuReprint
	{mso-style-name:bpuReprint;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:22.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.bpuSponsor, li.bpuSponsor, div.bpuSponsor
	{mso-style-name:bpuSponsor;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuState, li.bpuState, div.bpuState
	{mso-style-name:bpuState;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:32.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.charMarlett
	{mso-style-name:charMarlett;
	font-family:Marlett;}
p.ElevenPt, li.ElevenPt, div.ElevenPt
	{mso-style-name:ElevenPt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPage, li.FronterPage, div.FronterPage
	{mso-style-name:FronterPage;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPage12pt, li.FronterPage12pt, div.FronterPage12pt
	{mso-style-name:FronterPage12pt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageBillHeading, li.FronterPageBillHeading, div.FronterPageBillHeading
	{mso-style-name:FronterPageBillHeading;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.FronterPageTBox2, li.FronterPageTBox2, div.FronterPageTBox2
	{mso-style-name:FronterPageTBox2;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageTextBox, li.FronterPageTextBox, div.FronterPageTextBox
	{mso-style-name:FronterPageTextBox;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.FronterSameAs, li.FronterSameAs, div.FronterSameAs
	{mso-style-name:FronterSameAs;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.HangingAnAct, li.HangingAnAct, div.HangingAnAct
	{mso-style-name:HangingAnAct;
	mso-style-link:"HangingAnAct Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.HangingAnActChar
	{mso-style-name:"HangingAnAct Char";
	mso-style-link:HangingAnAct;
	letter-spacing:.2pt;}
span.Para10pt
	{mso-style-name:Para10pt;
	font-family:"Times New Roman",serif;}
p.Pg2Footer, li.Pg2Footer, div.Pg2Footer
	{mso-style-name:Pg2Footer;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.StyleFronterPage11pt, li.StyleFronterPage11pt, div.StyleFronterPage11pt
	{mso-style-name:"Style FronterPage + 11 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.StyleFronterPageLoweredby3pt, li.StyleFronterPageLoweredby3pt, div.StyleFronterPageLoweredby3pt
	{mso-style-name:"Style FronterPage + Lowered by  3 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	position:relative;
	top:3.0pt;}
p.StyleFronterSameAsPatternSolid100White, li.StyleFronterSameAsPatternSolid100White, div.StyleFronterSameAsPatternSolid100White
	{mso-style-name:"Style FronterSameAs + Pattern\: Solid \(100%\) \(White\)";
	margin:0in;
	margin-bottom:.0001pt;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Style1, li.Style1, div.Style1
	{mso-style-name:Style1;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.Whereas
	{mso-style-name:Whereas;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.Style10pt
	{mso-style-name:"Style 10 pt";
	font-family:"Times New Roman",serif;}
p.FronterPageNOCAPS, li.FronterPageNOCAPS, div.FronterPageNOCAPS
	{mso-style-name:FronterPageNOCAPS;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuWpGraphic, li.bpuWpGraphic, div.bpuWpGraphic
	{mso-style-name:bpuWpGraphic;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.sponUdate, li.sponUdate, div.sponUdate
	{mso-style-name:sponUdate;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.fronterpagebillhead
	{mso-style-name:fronterpagebillhead;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.FPHangingAnAct, li.FPHangingAnAct, div.FPHangingAnAct
	{mso-style-name:FPHangingAnAct;
	mso-style-link:"FPHangingAnAct Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.4in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.FPHangingAnActChar
	{mso-style-name:"FPHangingAnAct Char";
	mso-style-link:FPHangingAnAct;
	letter-spacing:.2pt;}
span.LeftBrackt
	{mso-style-name:LeftBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.RightBrackt
	{mso-style-name:RightBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.BoldItal
	{mso-style-name:BoldItal;
	font-weight:bold;
	font-style:italic;}
p.HangingSup, li.HangingSup, div.HangingSup
	{mso-style-name:HangingSup;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableBottom, li.HangingTableBottom, div.HangingTableBottom
	{mso-style-name:HangingTableBottom;
	margin-top:0in;
	margin-right:1.0in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableTop, li.HangingTableTop, div.HangingTableTop
	{mso-style-name:HangingTableTop;
	margin-top:0in;
	margin-right:.5in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Segoe UI",sans-serif;
	letter-spacing:.2pt;}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	mso-style-link:"Document Map";
	font-family:"Tahoma",sans-serif;
	background:navy;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;
	font-weight:bold;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-link:"Comment Text";
	letter-spacing:.2pt;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	letter-spacing:.2pt;
	font-weight:bold;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:8.5in 14.0in;
	margin:1.5in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
@page WordSection2
	{size:8.5in 14.0in;
	margin:1.0in 113.75pt 1.0in 113.75pt;}
div.WordSection2
	{page:WordSection2;}
@page WordSection3
	{size:8.5in 14.0in;
	margin:1.0in 1.75in 1.3in 2.0in;}
div.WordSection3
	{page:WordSection3;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US>

<div class=WordSection1>

<p class=bpuBill><a name=bpuFrontPg></a>SENATE, No. 3098 </p>

<p class=bpuWpGraphic><b><span style='font-size:32.0pt;line-height:120%;
font-family:"Arial",sans-serif;letter-spacing:0pt'>STATE OF NEW JERSEY</span></b></p>

<p class=bpuLegislature>221st LEGISLATURE</p>

<p class=bpuWpGraphic>  </p>

<p class=bpuIntro>INTRODUCED APRIL 11, 2024</p>

<p class=bpuIntro>&nbsp;</p>

</div>

<span style='font-size:11.0pt;line-height:120%;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:auto'>
</span>

<div class=WordSection2>

<p class=bpuIntro>&nbsp;</p>

<p class=bpuSponsor>Sponsored by:</p>

<p class=bpuSponsor>Senator  VIN GOPAL</p>

<p class=bpuSponsor>District 11 (Monmouth)</p>

<p class=bpuSponsor>Senator  TROY SINGLETON</p>

<p class=bpuSponsor>District 7 (Burlington)</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>Co-Sponsored by:</p>

<p class=bpuSponsor>Senators A.M.Bucco, Johnson, Greenstein, Pennacchio,
Diegnan, McKnight, Beach, Cruz-Perez, Zwicker and Bramnick</p>

<p class=MsoNormal>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=bpuSponsor>SYNOPSIS</p>

<p class=bpuNormText>     Requires health insurers to provide coverage for
biomarker testing. </p>

<p class=bpuNormText>&nbsp;</p>

<p class=bpuSponsor>CURRENT VERSION OF TEXT </p>

<p class=bpuNormText>     As introduced.</p>

<p class=bpuNormText>   </p>

</div>

<span style='font-size:12.0pt;line-height:120%;font-family:"Times New Roman",serif;
letter-spacing:.2pt'><br clear=all style='page-break-before:always'>
</span>

<div class=WordSection3>

<p class=HangingAnAct style='line-height:150%'><span class=BillHead>An Act</span><span
class=HangingAnActChar> </span>concerning health insurance coverage for
biomarker testing and amending and supplementing various parts of the statutory
law.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     <span class=BillHeading2>Be It
Enacted </span><span class=BillLanguage>by the Senate and General Assembly of
the State of New Jersey:</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     1.    a.  Each hospital
service corporation contract that provides hospital or medical expense benefits
and is delivered, issued, executed, or renewed in this State pursuant to
P.L.1938, c.366 (C.17:48-1 et seq.) or is approved for issuance or renewal in
this State by the Commissioner of Banking and Insurance, on or after the
effective date of P.L.    , c.     (C.        ) (pending before the Legislature
as this bill), shall provide coverage for biomarker testing, as defined by subsection
g. of this section.</p>

<p class=MsoNormal style='line-height:150%'>     b.    Biomarker testing shall
be covered for the purposes of diagnosis, treatment, appropriate management, or
ongoing monitoring of a disease or condition of a subscriber when the test is
supported by medical and scientific evidence, including, but not limited to:</p>

<p class=MsoNormal style='line-height:150%'>     (1)  labeled indications for
an FDA-approved or FDA-cleared test; </p>

<p class=MsoNormal style='line-height:150%'>     (2)  indicated tests for an
FDA-approved drug; </p>

<p class=MsoNormal style='line-height:150%'>     (3)  warnings and precautions
on FDA-approved drug labels;</p>

<p class=MsoNormal style='line-height:150%'>     (4)  Centers for Medicare and
Medicaid Services National Coverage Determinations or Medicare Administrative
Contractor Local Coverage Determinations; or</p>

<p class=MsoNormal style='line-height:150%'>     (5)  nationally-recognized
clinical practice guidelines and consensus statements.</p>

<p class=MsoNormal style='line-height:150%'>     c.    Coverage, pursuant to
subsection b. of this section, shall be provided in a manner that limits
disruption, including multiple biopsies or biospecimen samples, in the care of
a subscriber.</p>

<p class=MsoNormal style='line-height:150%'>     d.    (1)  Notwithstanding any
other law, rule, or regulation to the contrary, if utilization review is
required, a decision shall be rendered on a prior authorization request, and
notice shall be sent to the subscriber and the appropriate health care
provider, and if the request is made through a health care entity, to the
health care entity, within 72 hours for a non-urgent request or 24 hours for an
urgent request.</p>

<p class=MsoNormal style='line-height:150%'>     (2)  The subscriber and the
treating health care provider or treating health care entity prescribing
biomarker testing for the subscriber shall have access to clear, readily
accessible, and conspicuous information on the process to submit an appeal to
an adverse determination.</p>

<p class=MsoNormal style='line-height:150%'>     e.    The benefits shall be
provided to the same extent as for any other medical condition under the
contract.</p>

<p class=MsoNormal style='line-height:150%'>     f.     The provisions of this
section shall apply to all hospital service corporation contracts in which the
hospital service corporation has reserved the right to change the premium.</p>

<p class=MsoNormal style='line-height:150%'>     g.    As used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker means a
characteristic that is objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or pharmacologic responses
to a specific therapeutic intervention, including known gene-drug interactions
for medications being considered for use or already being administered.
Biomarkers shall also include, but not be limited to, gene mutations,
characteristics of genes, or protein expression.</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker testing means the
analysis of tissue, blood, or other biospecimen for the presence of a
biomarker.  Biomarker testing includes but is not limited to, single-analyte
tests, multiplex panel tests, protein expression, and whole exome, whole
genome, and whole transcriptome sequencing.</p>

<p class=MsoNormal style='line-height:150%'>     Consensus statement means a
statement developed by an independent, multidisciplinary panel of experts
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The statement shall be aimed at specific clinical
circumstances and be based on the best available evidence for the purpose of
optimizing the outcomes of clinical care.</p>

<p class=MsoNormal style='line-height:150%'>     Nationally-recognized
clinical practice guidelines means evidence-based clinical practice guidelines
developed by independent organizations or medical professional societies
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.<span style='font-size:11.5pt;line-height:150%'>  </span>The
guidelines establish standards of care informed by a systematic review of
evidence and an assessment of the benefits and risks of alternative care
options and include recommendations intended to optimize patient care.<span
style='font-size:11.5pt;line-height:150%'> </span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     2.    a.  Each medical service
corporation contract that provides hospital or medical expense benefits and is
delivered, issued, executed, or renewed in this State pursuant to P.L.1940,
c.74 (C.17:48A-1 et seq.) or is approved for issuance or renewal in this State
by the Commissioner of Banking and Insurance, on or after the effective date of
P.L. &nbsp;&nbsp;&nbsp;, c.     (C.        ) (pending before the Legislature as
this bill), shall provide coverage for biomarker testing, as defined by subsection
g. of this section.</p>

<p class=MsoNormal style='line-height:150%'>     b.    Biomarker testing shall
be covered for the purposes of diagnosis, treatment, appropriate management, or
ongoing monitoring of a disease or condition of a subscriber when the test is
supported by medical and scientific evidence, including, but not limited to:</p>

<p class=MsoNormal style='line-height:150%'>     (1)  labeled indications for
an FDA-approved or -cleared test; </p>

<p class=MsoNormal style='line-height:150%'>     (2)  indicated tests for an
FDA-approved drug; </p>

<p class=MsoNormal style='line-height:150%'>     (3)  warnings and precautions
on FDA-approved drug labels;</p>

<p class=MsoNormal style='line-height:150%'>     (4)  Centers for Medicare and
Medicaid Services National Coverage Determinations or Medicare Administrative
Contractor Local Coverage Determinations; or</p>

<p class=MsoNormal style='line-height:150%'>     (5)  nationally-recognized
clinical practice guidelines and consensus statements.</p>

<p class=MsoNormal style='line-height:150%'>     c.    Coverage, pursuant to
subsection b. of this section, shall be provided in a manner that limits
disruption, including multiple biopsies or biospecimen samples, in the care of
a subscriber.</p>

<p class=MsoNormal style='line-height:150%'>     d.    (1)  Notwithstanding any
other law, rule, or regulation to the contrary, if utilization review is
required, a decision shall be rendered on a prior authorization request, and notice
shall be sent to the subscriber and the appropriate health care provider, and
if the request is made through a health care entity, to the health care entity,
within 72 hours for a non-urgent request or 24 hours for an urgent request.</p>

<p class=MsoNormal style='line-height:150%'>     (2)  The subscriber and the
treating health care provider or treating health care entity prescribing
biomarker testing for the subscriber shall have access to clear, readily
accessible, and conspicuous information on the process to submit an appeal to
an adverse determination.</p>

<p class=MsoNormal style='line-height:150%'>     e.    The benefits shall be
provided to the same extent as for any other medical condition under the
contract.</p>

<p class=MsoNormal style='line-height:150%'>     f.     The provisions of this
section shall apply to all medical service corporation contracts in which the medical
service corporation has reserved the right to change the premium.</p>

<p class=MsoNormal style='line-height:150%'>     g.    As used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker means a
characteristic that is objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or pharmacologic responses
to a specific therapeutic intervention, including known gene-drug interactions
for medications being considered for use or already being administered.
Biomarkers shall also include, but not be limited to, gene mutations,
characteristics of genes, or protein expression.</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker testing means the
analysis of tissue, blood, or other biospecimen for the presence of a
biomarker.  Biomarker testing includes but is not limited to, single-analyte
tests, multiplex panel tests, protein expression, and whole exome, whole
genome, and whole transcriptome sequencing.</p>

<p class=MsoNormal style='line-height:150%'>     Consensus statement means a
statement developed by an independent, multidisciplinary panel of experts
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The statement shall be aimed at specific clinical
circumstances and be based on the best available evidence for the purpose of
optimizing the outcomes of clinical care.</p>

<p class=MsoNormal style='line-height:150%'>     Nationally-recognized
clinical practice guidelines means evidence-based clinical practice guidelines
developed by independent organizations or medical professional societies
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The guidelines establish standards of care informed by a
systematic review of evidence and an assessment of the benefits and risks of
alternative care options and include recommendations intended to optimize
patient care.<span style='font-size:11.5pt;line-height:150%'> </span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     3.    a.  Each health service
corporation contract that provides hospital or medical expense benefits and is
delivered, issued, executed, or renewed in this State pursuant to P.L.1985,
c.236 (C.17:48E-1 et seq.) or is approved for issuance or renewal in this State
by the Commissioner of Banking and Insurance, on or after the effective date of
P.L. &nbsp;&nbsp;&nbsp;, c.&nbsp; &nbsp; (C.        ) (pending before the
Legislature as this bill), shall provide coverage for biomarker testing, as
defined by subsection g. of this section.</p>

<p class=MsoNormal style='line-height:150%'>     b.    Biomarker testing shall
be covered for the purposes of diagnosis, treatment, appropriate management, or
ongoing monitoring of a disease or condition of a subscriber when the test is
supported by medical and scientific evidence, including, but not limited to:</p>

<p class=MsoNormal style='line-height:150%'>     (1)  labeled indications for
an FDA-approved or -cleared test; </p>

<p class=MsoNormal style='line-height:150%'>     (2)  indicated tests for an
FDA-approved drug; </p>

<p class=MsoNormal style='line-height:150%'>     (3)  warnings and precautions
on FDA-approved drug labels;</p>

<p class=MsoNormal style='line-height:150%'>     (4)  Centers for Medicare and
Medicaid Services National Coverage Determinations or Medicare Administrative
Contractor Local Coverage Determinations; or</p>

<p class=MsoNormal style='line-height:150%'>     (5)  nationally-recognized
clinical practice guidelines and consensus statements.</p>

<p class=MsoNormal style='line-height:150%'>     c.    Coverage, pursuant to
subsection b. of this section, shall be provided in a manner that limits disruption,
including multiple biopsies or biospecimen samples, in the care of a
subscriber.</p>

<p class=MsoNormal style='line-height:150%'>     d.    (1)  Notwithstanding any
other law, rule, or regulation to the contrary, if utilization review is
required, a decision shall be rendered on a prior authorization request, and
notice shall be sent to the subscriber and the appropriate health care
provider, and if the request is made through a health care entity, to the
health care entity, within 72 hours for a non-urgent request or 24 hours for an
urgent request.</p>

<p class=MsoNormal style='line-height:150%'>     (2)  The subscriber and the
treating health care provider or treating health care entity prescribing
biomarker testing for the subscriber shall have access to clear, readily
accessible, and conspicuous information on the process to submit an appeal to
an adverse determination.</p>

<p class=MsoNormal style='line-height:150%'>     e.    The benefits shall be
provided to the same extent as for any other medical condition under the
contract.</p>

<p class=MsoNormal style='line-height:150%'>     f.     The provisions of this
section shall apply to all health service corporation contracts in which the health
service corporation has reserved the right to change the premium.</p>

<p class=MsoNormal style='line-height:150%'>     g.    As used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker means a
characteristic that is objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or pharmacologic responses
to a specific therapeutic intervention, including known gene-drug interactions
for medications being considered for use or already being administered.
Biomarkers shall also include, but not be limited to, gene mutations,
characteristics of genes, or protein expression.</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker testing means the
analysis of tissue, blood, or other biospecimen for the presence of a
biomarker.  Biomarker testing includes but is not limited to, single-analyte
tests, multiplex panel tests, protein expression, and whole exome, whole
genome, and whole transcriptome sequencing.</p>

<p class=MsoNormal style='line-height:150%'>     Consensus statement means a
statement developed by an independent, multidisciplinary panel of experts
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The statement shall be aimed at specific clinical
circumstances and be based on the best available evidence for the purpose of
optimizing the outcomes of clinical care.</p>

<p class=MsoNormal style='line-height:150%'>     Nationally-recognized
clinical practice guidelines means evidence-based clinical practice guidelines
developed by independent organizations or medical professional societies
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The guidelines establish standards of care informed by a
systematic review of evidence and an assessment of the benefits and risks of
alternative care options and include recommendations intended to optimize
patient care.<span style='font-size:11.5pt;line-height:150%'> </span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     4.    a.  Each individual
health insurance policy that provides hospital or medical expense benefits and
is delivered, issued, executed, or renewed in this State pursuant to chapter 26
of Title 17B of the New Jersey Statutes or is approved for issuance or renewal
in this State by the Commissioner of Banking and Insurance, on or after the
effective date of P.L. &nbsp;&nbsp;&nbsp;, c.&nbsp; &nbsp; (C.        ) (pending
before the Legislature as this bill), shall provide coverage for biomarker
testing, as defined by subsection g. of this section.</p>

<p class=MsoNormal style='line-height:150%'>     b.    Biomarker testing shall
be covered for the purposes of diagnosis, treatment, appropriate management, or
ongoing monitoring of a disease or condition of an insured when the test is
supported by medical and scientific evidence, including, but not limited to:</p>

<p class=MsoNormal style='line-height:150%'>     (1)  labeled indications for
an FDA-approved or -cleared test; </p>

<p class=MsoNormal style='line-height:150%'>     (2)  indicated tests for an
FDA-approved drug; </p>

<p class=MsoNormal style='line-height:150%'>     (3)  warnings and precautions
on FDA-approved drug labels;</p>

<p class=MsoNormal style='line-height:150%'>     (4)  Centers for Medicare and
Medicaid Services National Coverage Determinations or Medicare Administrative
Contractor Local Coverage Determinations; or</p>

<p class=MsoNormal style='line-height:150%'>     (5)  nationally-recognized
clinical practice guidelines and consensus statements.</p>

<p class=MsoNormal style='line-height:150%'>     c.    Coverage, pursuant to
subsection b. of this section, shall be provided in a manner that limits
disruption, including multiple biopsies or biospecimen samples, in the care of
an insured.</p>

<p class=MsoNormal style='line-height:150%'>     d.    (1)  Notwithstanding any
other law, rule, or regulation to the contrary, if utilization review is
required, a decision shall be rendered on a prior authorization request, and
notice shall be sent to the insured and the appropriate health care provider,
and if the request is made through a health care entity, to the health care
entity, within 72 hours for a non-urgent request or 24 hours for an urgent
request.</p>

<p class=MsoNormal style='line-height:150%'>     (2)  The insured and the
treating health care provider or treating health care entity prescribing
biomarker testing for the insured shall have access to clear, readily
accessible, and conspicuous information on the process to submit an appeal to
an adverse determination.</p>

<p class=MsoNormal style='line-height:150%'>     e.    The benefits shall be
provided to the same extent as for any other medical condition under the
contract.</p>

<p class=MsoNormal style='line-height:150%'>     f.     The provisions of this
section shall apply to all health benefits plans in which the carrier has
reserved the right to change the premium.</p>

<p class=MsoNormal style='line-height:150%'>     g.    As used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker means a
characteristic that is objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or pharmacologic responses
to a specific therapeutic intervention, including known gene-drug interactions
for medications being considered for use or already being administered.
Biomarkers shall also include, but not be limited to, gene mutations,
characteristics of genes, or protein expression.</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker testing means the
analysis of tissue, blood, or other biospecimen for the presence of a biomarker. 
Biomarker testing includes but is not limited to, single-analyte tests, multiplex
panel tests, protein expression, and whole exome, whole genome, and whole
transcriptome sequencing.</p>

<p class=MsoNormal style='line-height:150%'>     Consensus statement means a
statement developed by an independent, multidisciplinary panel of experts
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The statement shall be aimed at specific clinical
circumstances and be based on the best available evidence for the purpose of
optimizing the outcomes of clinical care.</p>

<p class=MsoNormal style='line-height:150%'>     Nationally-recognized
clinical practice guidelines means evidence-based clinical practice guidelines
developed by independent organizations or medical professional societies
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The guidelines establish standards of care informed by a
systematic review of evidence and an assessment of the benefits and risks of
alternative care options and include recommendations intended to optimize
patient care.<span style='font-size:11.5pt;line-height:150%'> </span></p>

<p class=MsoNormal style='line-height:150%'>     5.    a.  Each group health
insurance policy that provides hospital or medical expense benefits and is
delivered, issued, executed, or renewed in this State pursuant to chapter 27 of
Title 17B of the New Jersey Statutes or is approved for issuance or renewal in
this State by the Commissioner of Banking and Insurance, on or after the
effective date of P.L. &nbsp;&nbsp;&nbsp;, c.&nbsp; &nbsp; (C.        ) (pending
before the Legislature as this bill), shall provide benefits for biomarker
testing, as defined by subsection g. of this section.</p>

<p class=MsoNormal style='line-height:150%'>     b.    Biomarker testing shall
be covered for the purposes of diagnosis, treatment, appropriate management, or
ongoing monitoring of a disease or condition of an insured when the test is
supported by medical and scientific evidence, including, but not limited to:</p>

<p class=MsoNormal style='line-height:150%'>     (1)  labeled indications for
an FDA-approved or -cleared test; </p>

<p class=MsoNormal style='line-height:150%'>     (2)  indicated tests for an
FDA-approved drug; </p>

<p class=MsoNormal style='line-height:150%'>     (3)  warnings and precautions
on FDA-approved drug labels;</p>

<p class=MsoNormal style='line-height:150%'>     (4)  Centers for Medicare and
Medicaid Services National Coverage Determinations or Medicare Administrative
Contractor Local Coverage Determinations; or</p>

<p class=MsoNormal style='line-height:150%'>     (5)  nationally-recognized
clinical practice guidelines and consensus statements.</p>

<p class=MsoNormal style='line-height:150%'>     c.    Coverage, pursuant to
subsection b. of this section, shall be provided in a manner that limits
disruption, including multiple biopsies or biospecimen samples, in the care of
an insured.</p>

<p class=MsoNormal style='line-height:150%'>     d.    (1)  Notwithstanding any
other law, rule, or regulation to the contrary, if utilization review is
required, a decision shall be rendered on a prior authorization request, and
notice shall be sent to the insured and the appropriate health care provider,
and if the request is made through a health care entity, to the health care
entity, within 72 hours for a non-urgent request or 24 hours for an urgent
request.</p>

<p class=MsoNormal style='line-height:150%'>     (2)  The insured and the
treating health care provider or treating health care entity prescribing
biomarker testing for the insured shall have access to clear, readily
accessible, and conspicuous information on the process to submit an appeal to
an adverse determination.</p>

<p class=MsoNormal style='line-height:150%'>     e.    The benefits shall be
provided to the same extent as for any other medical condition under the
contract.</p>

<p class=MsoNormal style='line-height:150%'>     f.     The provisions of this
section shall apply to all policies in which the insurer has reserved the right
to change the premium.</p>

<p class=MsoNormal style='line-height:150%'>     g.    As used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker means a
characteristic that is objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or pharmacologic responses
to a specific therapeutic intervention, including known gene-drug interactions
for medications being considered for use or already being administered.
Biomarkers shall also include, but not be limited to, gene mutations,
characteristics of genes, or protein expression.</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker testing means the
analysis of tissue, blood, or other biospecimen for the presence of a
biomarker.  Biomarker testing includes but is not limited to, single-analyte
tests, multiplex panel tests, protein expression, and whole exome, whole genome,
and whole transcriptome sequencing.</p>

<p class=MsoNormal style='line-height:150%'>     Consensus statement means a
statement developed by an independent, multidisciplinary panel of experts
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The statement shall be aimed at specific clinical
circumstances and be based on the best available evidence for the purpose of
optimizing the outcomes of clinical care.</p>

<p class=MsoNormal style='line-height:150%'>     Nationally-recognized
clinical practice guidelines means evidence-based clinical practice guidelines
developed by independent organizations or medical professional societies
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The guidelines establish standards of care informed by a
systematic review of evidence and an assessment of the benefits and risks of
alternative care options and include recommendations intended to optimize
patient care.<span style='font-size:11.5pt;line-height:150%'> </span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     6.    a.  Each individual
health benefits plan that provides hospital or medical expense benefits and is
delivered, issued, executed, or renewed in this State pursuant to P.L.1992,
c.161 (C.17B:27A-2 et seq.) or is approved for issuance or renewal in this
State by the Commissioner of Banking and Insurance, on or after the effective
date of P.L. &nbsp;&nbsp;&nbsp;, c.    (C.        ) (pending before the
Legislature as this bill), shall provide benefits for biomarker testing, as
defined by subsection g. of this section.&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     b.    Biomarker testing shall
be covered for the purposes of diagnosis, treatment, appropriate management, or
ongoing monitoring of a disease or condition of a covered person when the test
is supported by medical and scientific evidence, including, but not limited to:</p>

<p class=MsoNormal style='line-height:150%'>     (1)  labeled indications for
an FDA-approved or -cleared test; </p>

<p class=MsoNormal style='line-height:150%'>     (2)  indicated tests for an
FDA-approved drug; </p>

<p class=MsoNormal style='line-height:150%'>     (3)  warnings and precautions
on FDA-approved drug labels;</p>

<p class=MsoNormal style='line-height:150%'>     (4)  Centers for Medicare and
Medicaid Services National Coverage Determinations or Medicare Administrative
Contractor Local Coverage Determinations; or</p>

<p class=MsoNormal style='line-height:150%'>     (5)  nationally-recognized
clinical practice guidelines and consensus statements.</p>

<p class=MsoNormal style='line-height:150%'>     c.    Coverage, pursuant to
subsection b. of this section, shall be provided in a manner that limits
disruption, including multiple biopsies or biospecimen samples, in the care of
a covered person.</p>

<p class=MsoNormal style='line-height:150%'>     d.    (1)  Notwithstanding any
other law, rule, or regulation to the contrary, if utilization review is
required, a decision shall be rendered on a prior authorization request, and
notice shall be sent to the covered person and the appropriate health care
provider, and if the request is made through a health care entity, to the
health care entity, within 72 hours for a non-urgent request or 24 hours for an
urgent request.</p>

<p class=MsoNormal style='line-height:150%'>     (2)  The covered person and
the treating health care provider or treating health care entity prescribing
biomarker testing for the covered person shall have access to clear, readily
accessible, and conspicuous information on the process to submit an appeal to
an adverse determination.</p>

<p class=MsoNormal style='line-height:150%'>     e.    The benefits shall be
provided to the same extent as for any other medical condition under the health
benefits plan.</p>

<p class=MsoNormal style='line-height:150%'>     f.     The provisions of this
section shall apply to all health benefits plans in which the carrier has
reserved the right to change the premium.</p>

<p class=MsoNormal style='line-height:150%'>     g.    As used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker means a
characteristic that is objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or pharmacologic responses
to a specific therapeutic intervention, including known gene-drug interactions
for medications being considered for use or already being administered.
Biomarkers shall also include, but not be limited to, gene mutations,
characteristics of genes, or protein expression.</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker testing means the
analysis of tissue, blood, or other biospecimen for the presence of a
biomarker.  Biomarker testing includes but is not limited to, single-analyte
tests, multiplex panel tests, protein expression, and whole exome, whole
genome, and whole transcriptome sequencing.</p>

<p class=MsoNormal style='line-height:150%'>     Consensus statement means a
statement developed by an independent, multidisciplinary panel of experts
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The statement shall be aimed at specific clinical circumstances
and be based on the best available evidence for the purpose of optimizing the
outcomes of clinical care.</p>

<p class=MsoNormal style='line-height:150%'>     Nationally-recognized
clinical practice guidelines means evidence-based clinical practice guidelines
developed by independent organizations or medical professional societies
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The guidelines establish standards of care informed by a
systematic review of evidence and an assessment of the benefits and risks of
alternative care options and include recommendations intended to optimize
patient care.<span style='font-size:11.5pt;line-height:150%'> </span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     7.    a.  Each small employer
health benefits plan that provides hospital or medical expense benefits and is
delivered, issued, executed, or renewed in this State pursuant to P.L.1992,
c.162 (C.17B:27A-17 et seq.) or is approved for issuance or renewal in this
State by the Commissioner of Banking and Insurance, on or after the effective
date of P.L. &nbsp;&nbsp;&nbsp;, c.&nbsp; &nbsp; (C.        ) (pending before
the Legislature as this bill), shall provide benefits for biomarker testing, as
defined by subsection g. of this section.&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     b.    Biomarker testing shall
be covered for the purposes of diagnosis, treatment, appropriate management, or
ongoing monitoring of a disease or condition of a covered person when the test
is supported by medical and scientific evidence, including, but not limited to:</p>

<p class=MsoNormal style='line-height:150%'>     (1)  labeled indications for
an FDA-approved or -cleared test; </p>

<p class=MsoNormal style='line-height:150%'>     (2)  indicated tests for an
FDA-approved drug; </p>

<p class=MsoNormal style='line-height:150%'>     (3)  warnings and precautions
on FDA-approved drug labels;</p>

<p class=MsoNormal style='line-height:150%'>     (4)  Centers for Medicare and
Medicaid Services National Coverage Determinations or Medicare Administrative
Contractor Local Coverage Determinations; or</p>

<p class=MsoNormal style='line-height:150%'>     (5)  nationally-recognized
clinical practice guidelines and consensus statements.</p>

<p class=MsoNormal style='line-height:150%'>     c.    Coverage, pursuant to
subsection b. of this section, shall be provided in a manner that limits
disruption, including multiple biopsies or biospecimen samples, in the care of
a covered person.</p>

<p class=MsoNormal style='line-height:150%'>     d.    (1)  Notwithstanding any
other law, rule, or regulation to the contrary, if utilization review is
required, a decision shall be rendered on a prior authorization request, and
notice shall be sent to the covered person and the appropriate health care
provider, and if the request is made through a health care entity, to the
health care entity, within 72 hours for a non-urgent request or 24 hours for an
urgent request.</p>

<p class=MsoNormal style='line-height:150%'>     (2)  The covered person and
the treating health care provider or treating health care entity prescribing
biomarker testing for the covered person shall have access to clear, readily
accessible, and conspicuous information on the process to submit an appeal to
an adverse determination.</p>

<p class=MsoNormal style='line-height:150%'>     e.    The benefits shall be
provided to the same extent as for any other medical condition under the health
benefits plan.</p>

<p class=MsoNormal style='line-height:150%'>     f.     The provisions of this
section shall apply to all health benefits plans in which the carrier has
reserved the right to change the premium.</p>

<p class=MsoNormal style='line-height:150%'>     g.    As used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker means a
characteristic that is objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or pharmacologic responses
to a specific therapeutic intervention, including known gene-drug interactions
for medications being considered for use or already being administered.
Biomarkers shall also include, but not be limited to, gene mutations,
characteristics of genes, or protein expression.</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker testing means the
analysis of tissue, blood, or other biospecimen for the presence of a
biomarker.  Biomarker testing includes but is not limited to, single-analyte
tests, multiplex panel tests, protein expression, and whole exome, whole
genome, and whole transcriptome sequencing.</p>

<p class=MsoNormal style='line-height:150%'>     Consensus statement means a
statement developed by an independent, multidisciplinary panel of experts
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The statement shall be aimed at specific clinical
circumstances and be based on the best available evidence for the purpose of
optimizing the outcomes of clinical care.</p>

<p class=MsoNormal style='line-height:150%'>     Nationally-recognized
clinical practice guidelines means evidence-based clinical practice guidelines
developed by independent organizations or medical professional societies
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The guidelines establish standards of care informed by a
systematic review of evidence and an assessment of the benefits and risks of
alternative care options and include recommendations intended to optimize patient
care.<span style='font-size:11.5pt;line-height:150%'> </span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     8.      a.  Each health
maintenance organization contract for health care services that is delivered,
issued, executed, or renewed in this State pursuant to P.L.1973, c.337
(C.26:2J-1&nbsp;et&nbsp;seq.)&nbsp;or is approved for issuance or renewal in
this State by the Commissioner of Banking and Insurance, on or after the
effective date of P.L. &nbsp;&nbsp;&nbsp;, c. &nbsp;&nbsp; (C.        )
(pending before the Legislature as this bill), shall provide health care
services for biomarker testing, as defined by subsection g. of this section.</p>

<p class=MsoNormal style='line-height:150%'>     b.    Biomarker testing shall
be covered for the purposes of diagnosis, treatment, appropriate management, or
ongoing monitoring of a disease or condition of an enrollee when the test is
supported by medical and scientific evidence, including, but not limited to:</p>

<p class=MsoNormal style='line-height:150%'>     (1)  labeled indications for
an FDA-approved or -cleared test; </p>

<p class=MsoNormal style='line-height:150%'>     (2)  indicated tests for an
FDA-approved drug; </p>

<p class=MsoNormal style='line-height:150%'>     (3)  warnings and precautions
on FDA-approved drug labels;</p>

<p class=MsoNormal style='line-height:150%'>     (4)  Centers for Medicare and
Medicaid Services National Coverage Determinations or Medicare Administrative
Contractor Local Coverage Determinations; or</p>

<p class=MsoNormal style='line-height:150%'>     (5)  nationally-recognized
clinical practice guidelines and consensus statements.</p>

<p class=MsoNormal style='line-height:150%'>     c.    Coverage, pursuant to
subsection b. of this section, shall be provided in a manner that limits
disruption, including multiple biopsies or biospecimen samples, in the care of
an enrollee.</p>

<p class=MsoNormal style='line-height:150%'>     d.    (1)  Notwithstanding any
other law, rule, or regulation to the contrary, if utilization review is
required, a decision shall be rendered on a prior authorization request, and notice
shall be sent to the enrollee and the appropriate health care provider, and if
the request is made through a health care entity, to the health care entity,
within 72 hours for a non-urgent request or 24 hours for an urgent request. </p>

<p class=MsoNormal style='line-height:150%'>     (2)  The enrollee and the
treating health care provider or treating health care entity prescribing
biomarker testing for the enrollee shall have access to clear, readily
accessible, and conspicuous information on the process to submit an appeal to
an adverse determination.</p>

<p class=MsoNormal style='line-height:150%'>     e.    The health care services
shall be provided to the same extent as for any other medical condition under
the contract.</p>

<p class=MsoNormal style='line-height:150%'>     f.     The provisions of this
section shall apply to those contracts for health care services by health
maintenance organizations under which the right to change the schedule of
charges for enrollee coverage is reserved.</p>

<p class=MsoNormal style='line-height:150%'>     g.    As used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker means a
characteristic that is objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or pharmacologic responses
to a specific therapeutic intervention, including known gene-drug interactions
for medications being considered for use or already being administered.
Biomarkers shall also include, but not be limited to, gene mutations,
characteristics of genes, or protein expression.</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker testing means the
analysis of tissue, blood, or other biospecimen for the presence of a
biomarker.  Biomarker testing includes but is not limited to, single-analyte
tests, multiplex panel tests, protein expression, and whole exome, whole
genome, and whole transcriptome sequencing.</p>

<p class=MsoNormal style='line-height:150%'>     Consensus statement means a
statement developed by an independent, multidisciplinary panel of experts
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The statement shall be aimed at specific clinical
circumstances and be based on the best available evidence for the purpose of
optimizing the outcomes of clinical care.</p>

<p class=MsoNormal style='line-height:150%'>     Nationally-recognized
clinical practice guidelines means evidence-based clinical practice guidelines
developed by independent organizations or medical professional societies
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The guidelines establish standards of care informed by a
systematic review of evidence and an assessment of the benefits and risks of
alternative care options and include recommendations intended to optimize
patient care.<span style='font-size:11.5pt;line-height:150%'> </span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     9.      a.  The State Health
Benefits Commission shall ensure that every contract providing hospital or
medical expense benefits, which is purchased by the commission on or after the
effective date of P.L. &nbsp;&nbsp;&nbsp;, c.&nbsp; &nbsp; (C.        ) (pending
before the Legislature as this bill), provides coverage for biomarker testing,
as defined by subsection e. of this section.</p>

<p class=MsoNormal style='line-height:150%'>     b.    Biomarker testing shall
be covered for the purposes of diagnosis, treatment, appropriate management, or
ongoing monitoring of a disease or condition of a covered person when the test
is supported by medical and scientific evidence, including, but not limited to:</p>

<p class=MsoNormal style='line-height:150%'>     (1)  labeled indications for
an FDA-approved or -cleared test; </p>

<p class=MsoNormal style='line-height:150%'>     (2)  indicated tests for an
FDA-approved drug; </p>

<p class=MsoNormal style='line-height:150%'>     (3)  warnings and precautions
on FDA-approved drug labels;</p>

<p class=MsoNormal style='line-height:150%'>     (4)  Centers for Medicare and
Medicaid Services National Coverage Determinations or Medicare Administrative
Contractor Local Coverage Determinations; or</p>

<p class=MsoNormal style='line-height:150%'>     (5)  nationally-recognized
clinical practice guidelines and consensus statements.</p>

<p class=MsoNormal style='line-height:150%'>     c.    Coverage, pursuant to
subsection b. of this section, shall be provided in a manner that limits
disruption, including multiple biopsies or biospecimen samples, in the care of
a covered person.</p>

<p class=MsoNormal style='line-height:150%'>     d.    (1)  Notwithstanding any
other law, rule, or regulation to the contrary, if utilization review is
required, a decision shall be rendered on a prior authorization request, and
notice shall be sent to the covered person and the appropriate health care
provider, and if the request is made through a health care entity, to the
health care entity, within 72 hours for a non-urgent request or 24 hours for an
urgent request.</p>

<p class=MsoNormal style='line-height:150%'>     (2)  The covered person and
the treating health care provider or treating health care entity prescribing
biomarker testing to the covered person shall have access to clear, readily
accessible, and conspicuous information on the process to submit an appeal to
an adverse determination.</p>

<p class=MsoNormal style='line-height:150%'>     e.    As used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker means a
characteristic that is objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or pharmacologic responses
to a specific therapeutic intervention, including known gene-drug interactions
for medications being considered for use or already being administered.
Biomarkers shall also include, but not be limited to, gene mutations,
characteristics of genes, or protein expression.</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker testing means the
analysis of tissue, blood, or other biospecimen for the presence of a
biomarker.  Biomarker testing includes but is not limited to, single-analyte
tests, multiplex panel tests, protein expression, and whole exome, whole
genome, and whole transcriptome sequencing.</p>

<p class=MsoNormal style='line-height:150%'>     Consensus statement means a
statement developed by an independent, multidisciplinary panel of experts
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The statement shall be aimed at specific clinical
circumstances and be based on the best available evidence for the purpose of
optimizing the outcomes of clinical care.</p>

<p class=MsoNormal style='line-height:150%'>     Nationally-recognized
clinical practice guidelines means evidence-based clinical practice guidelines
developed by independent organizations or medical professional societies
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The guidelines establish standards of care informed by a
systematic review of evidence and an assessment of the benefits and risks of
alternative care options and include recommendations intended to optimize
patient care.<span style='font-size:11.5pt;line-height:150%'> </span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     10.    a.  The School
Employees Health Benefits Commission shall ensure that every contract
providing hospital or medical expense benefits, which is purchased by the
commission on or after the effective date of P.L. &nbsp;&nbsp;&nbsp;, c. &nbsp;&nbsp;
(C.        ) (pending before the Legislature as this bill), provides coverage
for biomarker testing, as defined by subsection e. of this section.</p>

<p class=MsoNormal style='line-height:150%'>     b.    Biomarker testing shall
be covered for the purposes of diagnosis, treatment, appropriate management, or
ongoing monitoring of a disease or condition of a covered person when the test
is supported by medical and scientific evidence, including, but not limited to:</p>

<p class=MsoNormal style='line-height:150%'>     (1)  labeled indications for
an FDA-approved or -cleared test; </p>

<p class=MsoNormal style='line-height:150%'>     (2)  indicated tests for an
FDA-approved drug; </p>

<p class=MsoNormal style='line-height:150%'>     (3)  warnings and precautions
on FDA-approved drug labels;</p>

<p class=MsoNormal style='line-height:150%'>     (4)  Centers for Medicare and
Medicaid Services National Coverage Determinations or Medicare Administrative
Contractor Local Coverage Determinations; or</p>

<p class=MsoNormal style='line-height:150%'>     (5)  nationally-recognized
clinical practice guidelines and consensus statements.</p>

<p class=MsoNormal style='line-height:150%'>     c.    Coverage, pursuant to
subsection b. of this section, shall be provided in a manner that limits
disruption, including multiple biopsies or biospecimen samples, in the care of
a covered person.</p>

<p class=MsoNormal style='line-height:150%'>     d.    (1)  Notwithstanding any
other law, rule, or regulation to the contrary, if utilization review is
required, a decision shall be rendered on a prior authorization request, and
notice shall be sent to the covered person and the appropriate health care
provider, and if the request is made through a health care entity, to the
health care entity, within 72 hours for a non-urgent request or 24 hours for an
urgent request.</p>

<p class=MsoNormal style='line-height:150%'>     (2)  The covered person and
the treating health care provider or treating health care entity prescribing
biomarker testing for the covered person shall have access to clear, readily
accessible, and conspicuous information on the process to submit an appeal to
an adverse determination.</p>

<p class=MsoNormal style='line-height:150%'>     e.    As used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker means a
characteristic that is objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or pharmacologic responses
to a specific therapeutic intervention, including known gene-drug interactions
for medications being considered for use or already being administered.
Biomarkers shall also include, but not be limited to, gene mutations,
characteristics of genes, or protein expression.</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker testing means the
analysis of tissue, blood, or other biospecimen for the presence of a
biomarker.  Biomarker testing includes but is not limited to, single-analyte
tests, multiplex panel tests, protein expression, and whole exome, whole
genome, and whole transcriptome sequencing.</p>

<p class=MsoNormal style='line-height:150%'>     Consensus statement means a
statement developed by an independent, multidisciplinary panel of experts
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The statement shall be aimed at specific clinical
circumstances and be based on the best available evidence for the purpose of
optimizing the outcomes of clinical care.</p>

<p class=MsoNormal style='line-height:150%'>     Nationally-recognized
clinical practice guidelines means evidence-based clinical practice guidelines
developed by independent organizations or medical professional societies
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The guidelines establish standards of care informed by a
systematic review of evidence and an assessment of the benefits and risks of
alternative care options and include recommendations intended to optimize
patient care.<span style='font-size:11.5pt;line-height:150%'> </span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     11.  a.  Notwithstanding any
State law or regulation to the contrary, the Department of Human Services shall
ensure that expenses incurred for biomarker testing shall be provided with no
cost-sharing to persons served under the Medicaid program, established pursuant
to P.L.1968, c.413 (C.30:4D-1&nbsp;et&nbsp;seq.).</p>

<p class=MsoNormal style='line-height:150%'>     b.    Biomarker testing shall
be covered for the purposes of diagnosis, treatment, appropriate management, or
ongoing monitoring of a disease or condition of an individual when the test is
supported by medical and scientific evidence, including, but not limited to:</p>

<p class=MsoNormal style='line-height:150%'>     (1)  labeled indications for
an FDA-approved or -cleared test; </p>

<p class=MsoNormal style='line-height:150%'>     (2)  indicated tests for an
FDA-approved drug; </p>

<p class=MsoNormal style='line-height:150%'>     (3)  warnings and precautions
on FDA-approved drug labels;</p>

<p class=MsoNormal style='line-height:150%'>     (4)  Centers for Medicare and
Medicaid Services National Coverage Determinations or Medicare Administrative
Contractor Local Coverage Determinations; or</p>

<p class=MsoNormal style='line-height:150%'>     (5)  nationally-recognized
clinical practice guidelines and consensus statements.</p>

<p class=MsoNormal style='line-height:150%'>     c.    Coverage, pursuant to
subsection b. of this section, shall be provided in a manner that limits
disruption, including multiple biopsies or biospecimen samples, in the care of
an individual.</p>

<p class=MsoNormal style='line-height:150%'>     d.    If the Division of
Medical Assistance and Health Services in the Department of Human Services
contracts with a third-party entity to deliver biomarker testing services pursuant
to this section to beneficiaries under the Medicaid program, the third-party
entity shall provide biomarker testing at the same scope, duration and
frequency as the Medicaid program otherwise provides to individuals.</p>

<p class=MsoNormal style='line-height:150%'>     e.    (1)  Notwithstanding any
other law, rule, or regulation to the contrary, if utilization review is
required, a decision shall be rendered on a prior authorization request, and
notice be sent to an individual, the appropriate health care provider, and, if
necessary, the requisite health care entity if the request for prior
authorization was submitted through the entity, within 72 hours for a
non-urgent request or 24 hours for an urgent request.</p>

<p class=MsoNormal style='line-height:150%'>     (2)  The individual and the
treating health care provider or treating health care entity prescribing
biomarker testing for the individual shall have access to clear, readily
accessible, and conspicuous information on the process to submit an appeal to
an adverse determination.</p>

<p class=MsoNormal style='line-height:150%'>     f.     As used in this
section:</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker means a
characteristic that is objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or pharmacologic responses
to a specific therapeutic intervention, including known gene-drug interactions
for medications being considered for use or already being administered.
Biomarkers shall also include, but not be limited to, gene mutations,
characteristics of genes, or protein expression.</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker testing means the
analysis of tissue, blood, or other biospecimen for the presence of a
biomarker.  Biomarker testing includes but is not limited to, single-analyte
tests, multiplex panel tests, protein expression, and whole exome, whole
genome, and whole transcriptome sequencing.<span style='font-size:11.5pt;
line-height:150%'> </span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     12.  This act shall take
effect on the 90th day next following enactment and shall apply to policies and
contracts issued or renewed on or after the effective date.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:150%'>STATEMENT</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     This bill requires health
insurers to cover biomarker testing.  Under the bill, health insurance carriers
(including health service corporations, hospital service corporations, medical
service corporations, commercial individual and group health insurers, health
maintenance organizations, entities contracted to administer health benefits in
connection with the State Health Benefits Program and School Employees Health
Benefits Program, and Medicaid) are to cover testing for the purposes of
diagnosis, treatment, appropriate management, or ongoing monitoring of an
individuals disease or condition when the test is supported by medical and
scientific evidence.  The evidence includes, but is not limited to: (1) labeled
indications for an FDA-approved or -cleared test;        (2)       indicated
tests for an FDA-approved drug; (3)       warnings and precautions on
FDA-approved drug labels; (4)        Centers for Medicare and Medicaid Services
National Coverage Determinations or Medicare Administrative Contractor Local <br
clear=all style='page-break-before:always'>
Coverage Determinations; or (5)      Nationally recognized clinical practice
guidelines and consensus statements.  Coverage is to be provided in a manner
that limits disruption, including multiple biopsies or biospecimen samples, in
the care of an individual.  The bill also stipulates timelines in which a
decision on prior authorization is to be made.   </p>

</div>

</body>

</html>
